Guggenheim Reiterates “Buy” Rating for Guardant Health (NASDAQ:GH)
Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday morning,Benzinga reports. The firm currently has a $56.00 price target on the stock. Several other brokerages also recently issued reports on GH. Raymond James reiterated an “outperform” rating and issued a $59.00 target price (up […]
Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday morning,Benzinga reports. The firm currently has a $56.00 price target on the stock. Several other brokerages also recently issued reports on GH. Raymond James reiterated an “outperform” rating and issued a $59.00 target price (up […]
